ITFI20100159A1 - Composizione per il trattamento e la prevenzione dell'herpes simplex labiale. - Google Patents
Composizione per il trattamento e la prevenzione dell'herpes simplex labiale. Download PDFInfo
- Publication number
- ITFI20100159A1 ITFI20100159A1 IT000159A ITFI20100159A ITFI20100159A1 IT FI20100159 A1 ITFI20100159 A1 IT FI20100159A1 IT 000159 A IT000159 A IT 000159A IT FI20100159 A ITFI20100159 A IT FI20100159A IT FI20100159 A1 ITFI20100159 A1 IT FI20100159A1
- Authority
- IT
- Italy
- Prior art keywords
- acid
- composition according
- echinacea
- mimosa
- carboxymethyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 14
- 208000009889 Herpes Simplex Diseases 0.000 title claims description 6
- 230000002265 prevention Effects 0.000 title claims description 3
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 16
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 10
- 229920002498 Beta-glucan Polymers 0.000 claims description 10
- 244000133098 Echinacea angustifolia Species 0.000 claims description 9
- 235000014134 echinacea Nutrition 0.000 claims description 9
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 8
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 8
- 229960000458 allantoin Drugs 0.000 claims description 8
- 229940101267 panthenol Drugs 0.000 claims description 8
- 239000011619 pantothenol Substances 0.000 claims description 8
- 235000020957 pantothenol Nutrition 0.000 claims description 8
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 7
- 229960003720 enoxolone Drugs 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- 229920001285 xanthan gum Polymers 0.000 claims description 6
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 4
- 235000011468 Albizia julibrissin Nutrition 0.000 claims description 4
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 241001070944 Mimosa Species 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000004287 Dehydroacetic acid Substances 0.000 claims description 2
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 claims description 2
- 229940061632 dehydroacetic acid Drugs 0.000 claims description 2
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019258 dehydroacetic acid Nutrition 0.000 claims description 2
- 229940107493 echinacea angustifolia root extract Drugs 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 229940082859 mimosa tenuiflora bark extract Drugs 0.000 claims description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
- 229940083542 sodium Drugs 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
- 208000004898 Herpes Labialis Diseases 0.000 description 5
- 206010067152 Oral herpes Diseases 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229960001438 immunostimulant agent Drugs 0.000 description 4
- 239000003022 immunostimulating agent Substances 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 206010001488 Aggression Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000016571 aggressive behavior Effects 0.000 description 3
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 2
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000978725 Mimosa tenuiflora Species 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- FSBUXLDOLNLABB-ISAKITKMSA-N echinacoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FSBUXLDOLNLABB-ISAKITKMSA-N 0.000 description 2
- NJYVDFDTLLZVMG-UHFFFAOYSA-N echinacoside Natural products CC1OC(OC2C(O)C(OCCc3ccc(O)c(O)c3)OC(COC4OC(CO)C(O)C(O)C4O)C2OC(=O)C=Cc5cc(O)cc(O)c5)C(O)C(O)C1O NJYVDFDTLLZVMG-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-WFJWTYAKSA-N (2s,4as,6as,6br,10s,12as)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid Chemical compound C12C(=O)C=C3C4C[C@@](C)(C(O)=O)CC[C@]4(C)CC[C@@]3(C)[C@]1(C)CCC1[C@]2(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-WFJWTYAKSA-N 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010065755 Lip infection Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
DESCRIZIONE
La presente invenzione riguarda una composizione per il trattamento e la prevenzione dell’herpes simplex labiale.
E’ noto che l’'herpes simplex à ̈ un genere di virus appartenente alla famiglia herpesviridae ed à ̈ causa di due forme di herpes: HSV I e HSV II. La prima forma, notevolmente diffusa, à ̈ responsabile della comparsa di vescicole febbrili caratteristiche che di norma interessano la cute facciale (labbra, narici); à ̈ detto anche herpes simplex labiale. Meno frequentemente, le vescicole possono formarsi sulla mucosa nasale (in partic. sulla parte esterna od interna delle narici), sulle guance o sul palato. Inizialmente, l'herpes labiale si manifesta con un leggero pizzicore e un senso di calore su un punto arrossato del labbro. Nel giro di poche ore, alcune vescicole ripiene di liquido limpido, spesso dolorose, cominciano a svilupparsi nella stessa zona del punto iniziale. Una volta terminato il processo infiammatorio, le vescicole provocate dall'herpes labiale si asciugano e formano una piccola crosta giallastra che scompare nel giro di 7-10 giorni, anche senza alcun trattamento. La comparsa dell'herpes labiale può coincidere con uno stato di malessere, nervosismo, una febbre, dopo l'inizio delle mestruazioni, uno stress, una intensa esposizione alla luce del sole o dopo aver mangiato particolari cibi. L'infezione provocata dall'herpes labiale ricompare con facilità poiché il virus sopravvive all'interno delle cellule e non viene eliminato neppure con l'impiego di farmaci efficaci.
Il trattamento in genere prevede l’utilizzo di farmaci topici a base di antivirali (aciclovir, famciclovir e valaciclovir) che però sono in grado di ridurre l’infezione senza eliminarla completamente.
Lo scopo principale della presente invenzione à ̈ quello di proporre una composizione che consenta di trattare e prevenire con efficacia l’insorgenza dell’Herpes simplex labiale.
A questo risultato si à ̈ pervenuti, in conformità della presente invenzione, adottando l’idea di realizzare una composizione avente le caratteristiche indicate nella rivendicazione 1. Altre caratteristiche della presente invenzione sono oggetto delle rivendicazioni dipendenti.
Grazie alla presente invenzione, à ̈ possibile trattare e prevenire efficacemente l’insorgenza dell’Herpes simplex labiale. Inoltre, una composizione in conformità della presente invenzione accelera la guarigione delle lesioni, allevia i sintomi associati, ed à ̈ di facile applicazione. In particolare, grazie alla presente invenzione si forma un biofilm, che impedisce alle vescicole della lesione di espandersi, protegge la lesione dalle aggressioni esterne, ed evita il dolore da secchezza, aria, calore ecc, ed à ̈ trasparente, il che fornisce un notevole vantaggio competitivo nei confronti dei principi attivi precedentemente menzionati (aciclovir ecc.) che sono di colore bianco molto evidente.
Questi ed ulteriori vantaggi e caratteristiche della presente invenzione saranno più e meglio compresi da ogni tecnico del ramo grazie alla descrizione che segue, nella quale sono indicati possibili esempi di realizzazione del trovato da non intendersi in senso limitativo.
Una composizione in conformità della presente invenzione si presenta in forma di idrogel e comprende aqua, sorbitol, xanthan gum, panthenol, Echinacea angustifolia root extract, Mimosa tenuiflora bark extract,sodium carboxymethyl betaglucan, allantoin, glycyrrhetinic acid, benzyl alcohol, dehydroacetic acid, disodium EDTA.
Più in particolare, una composizione in conformità della presente invenzione può
essere formulata come indicato nella tabella che segue:
Sostanza INCI NAME Funzione %
Est. Secco Echinacea Immunostimolante, 0,25-1% Echinacea tit. angustifolia antiinfiammatoria
4% root extract
echinacoside
Est. glicolico Mimosa Cicatrizzante, 2-4% mimosa tenuiflora bark protettivo, lenitivo,
extract antibatterico
Carbossimetil Aqua, sodium Immunostimolante 1-5% betaglucano carboxymethyl
sol. 2% betaglucan
Allantoina Allantoin Ammorbidente 0.3-0,5% cutaneo, lenitivo
Sorbitolo sol. Sorbitol, aqua Umettante, 5-20% 70% aromatizzante,
condizionante
Gomma Xanthan gum Gelificante 1-3% xantana
Isocide BAS Benzyl Conservante 0,5-2% alcohol,
dehydroacetic
acid
EDTA Disodium Sequestrante 0,1-0,2% disodico EDTA
Acido 18 β Glycyrrhetinic Antinifiammatorio 0,1-1% glicirretico acid
Pantenolo Panthenol Idratante, 0,5-3% filmogeno, lenitivo
Acqua Aqua Solvente a 100 depurata
Preferibilmente, le quantità delle sostanze indicate sono le seguenti:
Sostanza INCI NAME Funzione %
Est. Secco Echinacea Immunostimolante, 0,25 Echinacea tit. angustifolia antiinfiammatoria
4% root extract
echinacoside
Est. glicolico Mimosa Cicatrizzante, 2,5 mimosa tenuiflora bark protettivo, lenitivo,
extract antibatterico
Carbossimetil Aqua, sodium Immunostimolante 2 betaglucano carboxymethyl
sol. 2% betaglucan
Allantoina Allantoin Ammorbidente 0,3 cutaneo, lenitivo
Sorbitolo sol. Sorbitol, aqua Umettante, 10 70% aromatizzante,
condizionante
Gomma Xanthan gum Gelificante 2,2 xantana
Isocide BAS Benzyl Conservante 1 alcohol,
dehydroacetic
acid
EDTA Disodium Sequestrante 0,1 disodico EDTA
Acido 18 β Glycyrrhetinic Antinifiammatorio 0,15 glicirretico acid
Pantenolo Panthenol Idratante, 1 filmogeno, lenitivo
Acqua Aqua Solvente a 100 depurata
Le sostanze funzionali agiscono in sinergia per prevenire e contrastare le infezioni erpetiche labiali attraverso quattro diversi meccanismi:
1. formazione di un film protettivo contro le aggressioni esterne e contro al propagazione del virus ai tessuti adiacenti (pantenolo)
2. azione rinforzante le difese immunitarie, ad agire contro le aggressioni esterne (Carbossimetil-beta-glucano, estratto secco di Echinacea)
3. azione favorente la cicatrizzazione fisiologica (allantoina, estratto secco di Echinacea)
4. azione lenitiva (allantoina, pantenolo)
La composizione si applica sulle labbra formando un film protettivo. L’applicazione può essere ripetuta più volte nel corso della giornata.
Claims (6)
- RIVENDICAZIONI 1) Composizione per il trattamento e la prevenzione dell’herpes simplex labiale caratterizzata dal fatto che comprende, in associazione, le seguenti sostanze: Est. glicolico mimosa, Carbossimetil-beta-glucano, estratto secco di Echinacea, ed Acido 18 β glicirretico.
- 2) Composizione secondo la rivendicazione 1 caratterizzata dal fatto che comprende, in associazione, aqua, sorbitol, xanthan gum, panthenol, Echinacea angustifolia root extract, Mimosa tenuiflora bark extract,sodium carboxymethyl betaglucan, allantoin, glycyrrhetinic acid, benzyl alcohol, dehydroacetic acid, disodium EDTA.
- 3) Composizione secondo la rivendicazione 1 caratterizzata dal fatto che le sostanze indicate sono presenti nelle seguenti quantità : Acido 18 β 0,1-1%, Carbossimetil-beta-glucano 1-5%, estratto secco di Echinacea 0,25-1%, Est. glicolico mimosa 2-4%.
- 4) Composizione secondo la rivendicazione 1 caratterizzata dal fatto che le sostanze indicate sono presenti nelle seguenti quantità : Acido 18 β glicirretico 0.15%, Carbossimetil-beta-glucano 2%, estratto secco di Echinacea 0.25%, Est. glicolico mimosa 2.5%.
- 5) Composizione secondo una o più delle rivendicazioni precedenti caratterizzata dal fatto che à ̈ in forma di idrogel.
- 6) Composizione secondo una o più delle rivendicazioni precedenti caratterizzata dal fatto che à ̈ trasparente.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITFI2010A000159A IT1401083B1 (it) | 2010-07-27 | 2010-07-27 | Composizione per il trattamento e la prevenzione dell'herpes simplex labiale. |
| PCT/IT2011/000179 WO2012014238A1 (en) | 2010-07-27 | 2011-05-27 | Composition for the treatment and prevention of herpes simplex labialis |
| EP11738830.6A EP2598132B1 (en) | 2010-07-27 | 2011-05-27 | Composition for the treatment and prevention of herpes simplex labialis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITFI2010A000159A IT1401083B1 (it) | 2010-07-27 | 2010-07-27 | Composizione per il trattamento e la prevenzione dell'herpes simplex labiale. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ITFI20100159A1 true ITFI20100159A1 (it) | 2012-01-28 |
| IT1401083B1 IT1401083B1 (it) | 2013-07-12 |
Family
ID=43628688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ITFI2010A000159A IT1401083B1 (it) | 2010-07-27 | 2010-07-27 | Composizione per il trattamento e la prevenzione dell'herpes simplex labiale. |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2598132B1 (it) |
| IT (1) | IT1401083B1 (it) |
| WO (1) | WO2012014238A1 (it) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITUB20152286A1 (it) * | 2015-07-17 | 2017-01-17 | Harven S A S | Composizione anti herpes |
| FR3083450B1 (fr) | 2018-07-04 | 2021-05-07 | Laboratoire Mawena | Composition huileuse contenant un extrait de mimosa tenuiflora et utilisations |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2140809A (en) * | 1983-06-01 | 1984-12-05 | Biorex Laboratories Ltd | New derivatives of glycyrrhetinic acid |
| JPH06345748A (ja) * | 1993-06-15 | 1994-12-20 | Sanwa Kagaku Kenkyusho Co Ltd | 抗ウイルス活性を有する新規グリチルレチン酸誘導体 |
| WO2007059441A2 (en) * | 2005-11-10 | 2007-05-24 | Jose Angel Olalde Rangel | Synergistic phytoceutical compositions |
| WO2008010241A1 (en) * | 2006-07-18 | 2008-01-24 | D.M.G. Italia Srl | A liposomal complex of sodium carboxymethyl beta-glucan |
| WO2008134712A2 (en) * | 2007-04-30 | 2008-11-06 | Living Proof, Inc. | Use of matrix metalloproteinase inhibitors in skin care |
| WO2010045969A1 (en) * | 2008-10-21 | 2010-04-29 | Naturveda | New synergic association for the treatment of deep skin or mucosa injuries |
-
2010
- 2010-07-27 IT ITFI2010A000159A patent/IT1401083B1/it active
-
2011
- 2011-05-27 EP EP11738830.6A patent/EP2598132B1/en not_active Not-in-force
- 2011-05-27 WO PCT/IT2011/000179 patent/WO2012014238A1/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2140809A (en) * | 1983-06-01 | 1984-12-05 | Biorex Laboratories Ltd | New derivatives of glycyrrhetinic acid |
| JPH06345748A (ja) * | 1993-06-15 | 1994-12-20 | Sanwa Kagaku Kenkyusho Co Ltd | 抗ウイルス活性を有する新規グリチルレチン酸誘導体 |
| WO2007059441A2 (en) * | 2005-11-10 | 2007-05-24 | Jose Angel Olalde Rangel | Synergistic phytoceutical compositions |
| WO2008010241A1 (en) * | 2006-07-18 | 2008-01-24 | D.M.G. Italia Srl | A liposomal complex of sodium carboxymethyl beta-glucan |
| WO2008134712A2 (en) * | 2007-04-30 | 2008-11-06 | Living Proof, Inc. | Use of matrix metalloproteinase inhibitors in skin care |
| WO2010045969A1 (en) * | 2008-10-21 | 2010-04-29 | Naturveda | New synergic association for the treatment of deep skin or mucosa injuries |
Non-Patent Citations (1)
| Title |
|---|
| DATABASE WPI Week 199510, Derwent World Patents Index; AN 1995-070296, XP002627027 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IT1401083B1 (it) | 2013-07-12 |
| WO2012014238A1 (en) | 2012-02-02 |
| EP2598132A1 (en) | 2013-06-05 |
| EP2598132B1 (en) | 2014-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2319968T3 (es) | Composiciones de hierbas para el tratamiento de lesiones de la mucosa. | |
| ES2368974T3 (es) | Preparación que contiene osmolitos para uso en caso de membranas mucosas secas. | |
| ES2278393T3 (es) | Tratamiento antimicrobiano del virus herpes simplex y otras enfermedades infecciosas. | |
| Gavanji et al. | The effect of extract of Punica granatum var. pleniflora for treatment of minor recurrent aphthous stomatitis | |
| CA2613297C (en) | Composition for treating skin lesions | |
| KR20050007585A (ko) | 아프타 궤양 및 단순 헤르페스 병변의 예방 및 치료조성물 및 방법 | |
| EP2251016B1 (en) | Topical use of hyaluronic acid with filmogenic action for the treatment and prophylaxys of pathologies of the respiratory tract. | |
| JP5096921B2 (ja) | 経粘膜搬送デバイス | |
| ITRM20060163A1 (it) | Composizione spray ad uso topico per il tratamento e la prevenzione delle infezioni labiali da herpes simplex | |
| JP6461002B2 (ja) | 口腔局所用組成物 | |
| CA2783612A1 (en) | Composition for treating skin lesions | |
| ITFI20100159A1 (it) | Composizione per il trattamento e la prevenzione dell'herpes simplex labiale. | |
| ATE525063T1 (de) | Antivirale formulierung | |
| US20150359835A1 (en) | Composition of a medical device or cosmetic product based on grapefruit seed extract, lady's mantle leaf extract, stevia extract, and curcumin | |
| WO2011057363A1 (en) | Disposable device and uses thereof for skin and mucosal applications | |
| Singh et al. | Honey: Nature’s Wonder of Healing | |
| BE1019216A3 (nl) | Kleefpleister voor de toediening van therapeutische agentia. | |
| JP6830482B2 (ja) | 粘膜病変の治療のための配合物 | |
| Shanbhag | Aloe vera in the management of oral submucous fibrosis | |
| EP2441440A1 (en) | Natural pharmacological aid for prevention of periodontal inflammatory disease | |
| CN100387249C (zh) | 一种治疗溃疡的中药制剂 | |
| Alemrajabi et al. | Effects of Propolis and Persica Mouthwashes on Minor Aphthous Ulcers: A Comparative Study | |
| US20070059391A1 (en) | Antioxidant skin balm | |
| Srivastava et al. | Aloe vera: The herbal magic wand | |
| US20110229584A1 (en) | Compound for the control of herpes simplex virus using glycyrrhizic acid, lipoic acid, allantoin, and slippery elm |